CYP19A1 and breast carcinoma: Certain breast cancer survivors (BCS) who are diagnosed with hormone-receptor-positive breast cancer are prescribed endocrine (hormone) therapies (e.g., tamoxifen or aromatase inhibitors) to reduce the chance of recurrence of these cancers by nearly half [3].